IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1. (Currently amended) A transdermal delivery system (TDS) comprising a backing layer, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, wherein the self-adhesive matrix comprises a solid or semi-solid semi-permeable polymer
   (1) wherein rotigotine in its free base form is incorporated,
   (2) which comprises a multitude of microreservoirs within the matrix, said microreservoirs containing rotigotine ~~**and optionally at least a crystallization inhibitor**~~,
   (3) which is permeable to the free base of rotigotine,
   (4) which is substantially impermeable to the protonated form of rotigotine, and
   (5) wherein ~~**the maximum diameter of**~~ the microreservoirs **have a maximum diameter that** is less than the thickness of the matrix;

   and wherein the backing layer is inert to the components of the matrix.

2. (Currently amended) The TDS of claim 1, wherein ~~**the mean diameter of**~~ the microreservoirs **[[is]] have a mean diameter** in the range of 0.5 to 20 μm.

3. (Previously presented) The TDS of claim 1, wherein the self-adhesive matrix is free of particles that can absorb salts of rotigotine at the TDS/skin interface.

4. (Currently amended) The TDS of claim 1, wherein the ~~**polymer**~~ **self-adhesive** matrix comprises a silicone pressure sensitive adhesive.

5. (Currently amended) The TDS of claim 1, wherein the ~~**polymer**~~ **self-adhesive** matrix comprises two or more silicone pressure sensitive adhesives as the main adhesive components.

6. (Previously presented) The TDS of claim 5, wherein the two or more silicone pressure sensitive adhesives comprise a blend of a high tack silicone pressure sensitive adhesive

comprising polysiloxane with a resin and a medium tack silicone pressure sensitive adhesive comprising polysiloxane with a resin.

7. (Withdrawn) A method for treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the TDS of claim 1 to the skin of the patient.

8. (New) The TDS of claim 1, wherein the microreservoirs additionally contain at least one crystallization inhibitor comprising soluble polyvinylpyrrolidone, a copolymer of polyvinylpyrrolidone and vinyl acetate, polyethylene glycol, polypropylene glycol, glycerol, a fatty acid ester of glycerol and/or a copolymer of ethylene and vinyl acetate.

9. (New) The TDS of claim 8, wherein the at least one crystallization inhibitor comprises soluble polyvinylpyrrolidone.

10. (New) The TDS of claim 1, comprising within the matrix 10^3 to 10^9 microreservoirs per cm^2 of the surface of the matrix.

11. (New) The TDS of claim 1, comprising within the matrix 10^6 to 10^9 microreservoirs per cm^2 of the surface of the matrix.

12. (New) The TDS of Claim 1, wherein the microreservoirs have a maximum diameter not greater than 35 μm.

13. (New) The TDS of claim 1, wherein the microreservoirs have a maximum diameter of 2.5 to 30 μm.